Corteva (NYSE:CTVA) Price Target Raised to $90.00

Key Points

• Analyst price-target upgrades: UBS raised its target to $90 and several firms (Jefferies $97, Goldman $96, Wells Fargo $90) have lifted targets, leaving a consensus rating of "Moderate Buy" with an average price target of $86.95.
• Q1 beats and guidance: Corteva reported EPS $1.50 vs. $1.18 expected and revenue $4.91B vs. $4.64B (revenue +11% YoY), and reaffirmed FY‑2026 guidance of $3.450–3.700 EPS while remaining on track for a planned 4Q‑2026 separation.
• Shares traded near $79.14 (down $2.64) with a market cap of $53.13B, a PE of 46.55 and a 52‑week range of $60.53–$85.63; insiders own 0.15% while institutions hold about 81.5%.

Corteva (NYSE:CTVA - Get Free Report) had its target price upped by research analysts at UBS Group from $88.00 to $90.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. UBS Group's price objective indicates a potential upside of 13.73% from the stock's current price.

Several other brokerages also recently issued reports on CTVA. Jefferies Financial Group upped their price objective on Corteva from $95.00 to $97.00 in a research report on Thursday. Wells Fargo & Company upped their target price on Corteva from $85.00 to $90.00 and gave the company an "overweight" rating in a research note on Tuesday, April 21st. Rothschild & Co Redburn upped their target price on Corteva from $80.00 to $90.00 and gave the company a "neutral" rating in a research note on Wednesday, April 29th. The Goldman Sachs Group upped their target price on Corteva from $88.00 to $96.00 and gave the company a "buy" rating in a research note on Tuesday, April 14th. Finally, Bank of America upped their target price on Corteva from $80.00 to $82.00 and gave the company a "buy" rating in a research note on Thursday, January 8th. Fourteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $86.95.

Corteva Price Performance

Shares of NYSE:CTVA traded down $2.64 on Thursday, hitting $79.14. The company had a trading volume of 6,274,985 shares, compared to its average volume of 4,024,688. The company has a current ratio of 1.43, a quick ratio of 0.96 and a debt-to-equity ratio of 0.07. Corteva has a 52-week low of $60.53 and a 52-week high of $85.63. The business has a 50 day moving average of $80.66 and a 200 day moving average of $72.48. The company has a market cap of $53.13 billion, a PE ratio of 46.55, a PEG ratio of 2.88 and a beta of 0.59.

Corteva (NYSE:CTVA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.32. Corteva had a return on equity of 9.88% and a net margin of 6.50%.The business had revenue of $4.91 billion for the quarter, compared to the consensus estimate of $4.64 billion. During the same period in the prior year, the business earned $1.13 earnings per share. The business's revenue was up 11.0% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, equities analysts anticipate that Corteva will post 3.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Corteva news, insider Brian Titus sold 8,311 shares of the company's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $76.55, for a total transaction of $636,207.05. Following the completion of the sale, the insider directly owned 8,090 shares in the company, valued at $619,289.50. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.15% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Corteva

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Activest Wealth Management increased its stake in Corteva by 118.3% during the third quarter. Activest Wealth Management now owns 369 shares of the company's stock worth $25,000 after acquiring an additional 200 shares during the last quarter. JPL Wealth Management LLC acquired a new stake in shares of Corteva in the third quarter valued at about $25,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Corteva in the fourth quarter valued at about $27,000. Bank of Jackson Hole Trust purchased a new position in Corteva in the fourth quarter valued at about $28,000. Finally, Redmont Wealth Advisors LLC purchased a new position in Corteva in the third quarter valued at about $29,000. 81.54% of the stock is currently owned by institutional investors and hedge funds.

Corteva News Roundup

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Corteva reported a stronger‑than‑expected Q1 (EPS and revenue beats), reaffirmed its 2026 outlook and said it remains on track for the planned 4Q‑2026 separation — fundamental results that support upside. Corteva Agriscience: Corteva Delivers Strong 1Q 2026, Reaffirms 2026 Outlook, On-Track for 4Q 2026 Separation
• Positive Sentiment: Jefferies raised its price target to $97, implying sizable upside versus current levels — a bullish analyst signal that can support the stock. Jefferies adjusts price target on Corteva to $97 from $95
• Neutral Sentiment: Management (CEO Chuck Magro and CFO David Johnson) will present at the BMO Global Farm to Market conference on May 14 — an event where management can reiterate guidance and answer analyst questions, but not an immediate catalyst. Corteva to Participate in BMO Global Farm to Market Conference
• Neutral Sentiment: Transcripts and the earnings presentation are now available for deeper review — useful for investors who want detail on margins, regional demand and guidance drivers. Corteva, Inc. (CTVA) Q1 2026 Earnings Call Transcript
• Negative Sentiment: BNP Paribas Exane lifted its target only to $77, which sits below current market levels and signals some analyst caution about upside from here — a factor contributing to downward pressure. BNP Paribas adjusts price target on Corteva to $77 from $74

Corteva Company Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.